Literature DB >> 27443135

Pulmonary Arterial Hypertension: Diagnosis and Treatment.

Christopher F Barnett1, Paulino Alvarez2, Myung H Park3.   

Abstract

Pulmonary arterial hypertension (PAH) is a specific, rare disease characterized by a well-described pattern of pulmonary vascular remodeling. The elevated pulmonary artery pressure in PAH results in increased right ventricular afterload, which, if untreated, leads rapidly to right ventricular failure and death. Recent marked expansion in knowledge about PAH has resulted in the development of effective therapies that improve quality of life and survival. However, delays in diagnosis and suboptimal treatment remain significant barriers to achieving optimal patient outcomes. Continued success in raising PAH awareness, earlier diagnosis, and the availability of new therapies mean a promising future for PAH patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Echocardiography; Endothelin antagonist; Phosphodiesterase inhibitor; Prostacyclin; Pulmonary arterial hypertension; Right heart catheterization

Mesh:

Substances:

Year:  2016        PMID: 27443135     DOI: 10.1016/j.ccl.2016.04.006

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  9 in total

Review 1.  Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 Grover Conference series).

Authors:  Jarrod W Barnes; Adriano R Tonelli; Gustavo A Heresi; Jennie E Newman; Noël E Mellor; David E Grove; Raed A Dweik
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

2.  Things We "kNOw" and Do Not "kNOw" about Pulmonary Hypertension.

Authors:  Jarrod W Barnes; Rakesh P Patel
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

3.  Increased risk of mortality in systemic sclerosis-associated pulmonary hypertension: a systemic review and meta-analysis.

Authors:  Anji Xiong; Qingting Liu; Jiaxun Zhong; Yuzi Cao; Qilang Xiang; Ziyi Hu; Shifeng Zhou; Zhuoyao Song; Huini Chen; Yan Zhang; Hongxu Cui; Shiquan Shuai
Journal:  Adv Rheumatol       Date:  2022-03-30

Review 4.  Pulmonary Arterial Hypertension in Women.

Authors:  Humna Abid Memon; Myung H Park
Journal:  Methodist Debakey Cardiovasc J       Date:  2017 Oct-Dec

Review 5.  Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.

Authors:  Anhua Wei; Zhichun Gu; Juan Li; Xiaoyan Liu; Xiaofan Wu; Yi Han; Jun Pu
Journal:  J Am Heart Assoc       Date:  2016-10-26       Impact factor: 5.501

6.  Adding value to myocardial perfusion SPECT/CT studies that include coronary calcium CT: Detection of incidental pulmonary arterial dilatation.

Authors:  Charles Marcus; Prasanna Santhanam; Matthew J Kruse; Mehrbod S Javadi; Lilja B Solnes; Steven P Rowe
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

7.  MiR-629 regulates hypoxic pulmonary vascular remodelling by targeting FOXO3 and PERP.

Authors:  Mei Zhao; Ni Chen; Xuelian Li; Ling Lin
Journal:  J Cell Mol Med       Date:  2019-06-26       Impact factor: 5.310

8.  Lumped-Parameter Circuit Platform for Simulating Typical Cases of Pulmonary Hypertensions from Point of Hemodynamics.

Authors:  Hong Tang; Ziyin Dai; Miao Wang; Binbin Guo; Shunyu Wang; Jiabin Wen; Ting Li
Journal:  J Cardiovasc Transl Res       Date:  2020-01-13       Impact factor: 4.132

9.  Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer.

Authors:  Rosanna Sestito; Piera Tocci; Celia Roman; Valeriana Di Castro; Anna Bagnato
Journal:  J Exp Clin Cancer Res       Date:  2022-04-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.